Related Experiment Video
Updated: Feb 17, 2026
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
Published on: July 28, 2020
EJC's biennial report on metastatic soft tissue sarcoma: State of the art and future perspectives
Melissa Vos1, Stefan Sleijfer2
1Department of Medical Oncology, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands; Department of Surgical Oncology, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands.
Abstract:
In the last decade the limited treatment options for patients with metastatic soft tissue sarcoma have expanded considerably. With the addition of olaratumab to first-line treatment with doxorubicin, the introduction of several new agents in second-line treatment and beyond and other promising agents in the pipeline, perspectives of patients with metastatic soft tissue sarcoma are improving. Due to increasing insight into the biology of the different soft tissue sarcoma subtypes, choice of treatment has become much more histology-driven, although more prognostic and predictive factors are needed to further personalise therapy. This report summarises the current state of the art and discusses the promising developments in the treatment of patients with metastatic soft tissue sarcoma.
Insights
Treatment options for metastatic soft tissue sarcoma have significantly improved. New therapies and a better understanding of sarcoma biology are enhancing patient outcomes and personalizing treatment strategies.
Area of Science:
- Oncology
- Medical Science
Background:
- Limited treatment options previously existed for metastatic soft tissue sarcoma.
- Recent advancements have expanded therapeutic choices for patients.
Purpose of the Study:
- To summarize the current treatment landscape for metastatic soft tissue sarcoma.
- To discuss emerging therapies and future directions in sarcoma treatment.
Main Methods:
- Review of recent clinical trials and therapeutic developments.
- Analysis of evolving treatment strategies based on sarcoma histology.
Main Results:
- Addition of olaratumab to doxorubicin in first-line treatment.
- Introduction of multiple new agents for second-line and beyond treatment.
- Improved patient perspectives due to expanded therapeutic options.
Conclusions:
- Treatment for metastatic soft tissue sarcoma is becoming increasingly histology-driven.
- Further research is needed for more prognostic and predictive factors to personalize therapy.
- Promising developments indicate a positive outlook for patients with metastatic soft tissue sarcoma.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...